K-BIO Institute for Cell-Biotechnology and Immunology GmbH
CANCER IMMUNOTHERAPY, ΑΝΟΣΟΘΕΡΑΠΕΙΑ ΚΑΡΚΙΝΟΥ AHICE

INVESTOR INQUIRIES, CO-OPERATION NETWORK

Beside the remarkable therapeutic results of autologous vaccine AHICE, since year 2000 until now, on the fields of cancer as also on the field of auto-immune disorders, but on the meaningful field of prevention and anti-ageing too, we believe and wish us, that prerequisite to achieve the aims of our K-BIO Institute absolutely is to generate a

network of co-operating colleagues, international active,

from fields of medicinal-oncology, rheumatology, clinics/hospitals as well, who are willing to prepare by their responsibility and apply autologous cancer immunotherapy, autologous vaccine AHICE to their patients(request licences), accordint to ATMP regulation 1394/2007/EG,Article #6 ⇒ exemption from official manufacturing license for the new advanced immunotherapy AHICE for physicians in hospital or hospital for their autologous patients, compliant with §13, Article 2b German Drug Law AMG.

Investor inquiries are welcome

    who would support financially our scientific work, which is of highest ethical and most interesting economic level.

Ask for more Informations

 

K-BIO, Clinical Biochemical Institute for Cellbiotechnology and Immunology GmbH

 e-Mail: Info[at]K-BIO-Institut.net 

contact

 

 

MLC, MediLab-Consulting

Institute for lab-standardisation, lab-accreditation, reagents- and analyzers-supply for Medical-diagnostic laboratories  

 

e-Mail:  Info[at]K-BIO-Institut.net

 

 

 

We are pleasured to answer your needs.

 

   Home, Language <= back          next → Contact

 

                                                                                                          next → Impressum, English

ZurückWeiter
Top | Info@K-BIO-Institut.de